Sequence-based CYP2D6 genotyping in the Korean population

Therapeutic Drug Monitoring

Volumn 28, Issue 3, 2006, Pages 382-387

  Lee, Soo Youn ^a   Sohn, Kwang Min ^a   Ryu, Ji Young ^b   Yoon, Young Ran ^c   Shin, Jae Gook ^b   Kim, Jong Won ^a,d  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

^d Samsung Medical Center   (South Korea)

Author keywords

Asian; CYP2D6; Genotype; Nortriptyline; Pharmacogenetics

Indexed keywords

CYTOCHROME P450 2D6; NORTRIPTYLINE;

ALLELE; ARTICLE; CONCENTRATION (PARAMETERS); GENE ACTIVITY; GENE DUPLICATION; GENE FREQUENCY; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; METABOLISM; NORMAL HUMAN; PHARMACOGENETICS; POPULATION GENETICS; PRIORITY JOURNAL;

ADULT; ALLELES; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; GENOTYPE; HALF-LIFE; HUMANS; KOREA; MALE; METABOLIC CLEARANCE RATE; NORTRIPTYLINE; POLYMORPHISM, GENETIC;

EID: 33748210748     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000211823.80854.db     Document Type: Article

References (28)

1. Roh HK, Dahl ML, Johansson I, et al. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics. 1996;6:441-447.
2. Sohn DR, Shin SG, Park CW, et al. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol. 1991;32:504-507.
3. Yoon YR, Cha IJ, Shon JH, et al. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin Pharmacol Ther. 2000;67:567-576.
4. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229-243.
5. Bertilsson L, Dahl ML, Dalen P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53:111-122.
6. Sachse CBJ, Bauer S, Roots I. Cytochrome 450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295.
7. Hammer W, Sjoqvist F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci. 1967;6:1895-1903.
8. Bertilsson L, Mellstrom B, Sjokvist F, et al. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet. 1981;1:560-561.
9. Dalen P, Dahl ML, Ruiz ML, et al. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther. 1998;63:444-452.
10. Soyama A, Kubo T, Miyajima A, et al. Novel nonsynonymous single nucleotide polymorphisms in the CYP2D6 gene. Drug Metab Pharmacokinet. 2004;19:313-319.
11. Lovlie R, Daly AK, Molven A, et al. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996;392:30-34.
12. Ishiguro A, Kubota T, Sasaki H, et al. A long PCR assay to distinguish CYP2D6*5 and a novel CYP2D6 mutant allele associated with an 11-kb EcoRI haplotype. Clin Chim Acta. 2004;347:217-221.
13. Hersberger M, Marti-Jaun J, Rentsch K, et al. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem. 2000;46:1072-1077.
14. Ji L, Pan S, Marti-Jaun J, et al. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem. 2002;48:983-988.
15. Ghahramani P, Lennard MS. Quantitative analysis of amitriptyline and nortriptyline in human plasma and liver microsomal preparations by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996;685:307-313.
16. Garcia-Barcelo M, Chow LY, Chiu HF, et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem. 2000;46:18-23.
17. Wan YJ, Poland RE, Han G, et al. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics. 2001;11:489-499.
18. Nishida Y, Fukuda T, Yamamoto I, et al. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics. 2000;10:567-570.
19. Yoon YRCI, Shon JH, Kim KA, et al. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2S6*10 genotype of Korean subjects. Clin Pharmacol Ther. 2000;67:567-576.
20. Raimundo S, Toscano C, Klein K, et al. A novel intronic mutation, 2988G > A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther. 2004;76:128-138.
21. Mitsunaga Y, Kubota T, Ishiguro A, et al. Frequent occurrence of CYP2D6*10 duplication allele in a Japanese population. Mutat Res. 2002;505:83-85.
22. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104:173-192.
23. Dalen P, Dahl ML, Roh HK, et al. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. Br J Clin Pharmacol. 2003;55:630-634.
24. Morita S, Shimoda K, Someya T, et al. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J Clin Psychopharmacol. 2000;20:141-149.
25. Kvist EE, Al-Shurbaji A, Dahl ML, et al. Quantitative pharmacogenetics of nortriptyline: a novel approach. Clin Pharmacokinet. 2001;40:869-877.
26. Murphy GM Jr, Pollock BG, Kirshner MA, et al. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology. 2001;25:737-743.
27. Steimer W, Zopf K, von Amelunxen S, et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem. 2004;50:1623-1633.
28. Yue QY, Zhong ZH, Tybring G, et al. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther. 1998;64:384-390.